Enzokast-AB Tablet SR is a sustained-release formulation combining Acebrophylline 200mg and Montelukast 10mg, designed for the management of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates airway clearance by reducing mucus viscosity and improving bronchial airflow, thereby alleviating bronchospasm and enhancing respiratory function. Montelukast, a selective leukotriene receptor antagonist, inhibits leukotriene-mediated bronchoconstriction, inflammation, and edema, contributing to long-term control of airway hyperresponsiveness and prevention of asthma exacerbations. The sustained-release mechanism ensures prolonged therapeutic effects, promoting patient compliance through once-daily dosing. Enzokast-AB is indicated for patients requiring combined bronchodilator and anti-inflammatory therapy to improve pulmonary function and reduce symptoms such as wheezing, breathlessness, and cough. It is particularly beneficial in cases where monotherapy is insufficient to achieve optimal control. The medication should be used under medical supervision, with attention to contraindications such as hypersensitivity to components, and caution in patients with hepatic or renal impairment. Adverse effects may include headache, gastrointestinal disturbances, and rare hypersensitivity reactions. Regular monitoring and adherence to prescribed dosage are essential for maximizing therapeutic outcomes.